ANTX
AN2 Therapeutics, Inc.
$4.42
-0.28 (-5.96%)
At close · Jul 2
Market Cap
$159.19M
Shares
36,016,161
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.42
Open$4.71
Day$4.41–4.78
52W$1.00–6.91
Avg vol 30d350K
Short int1.3M · 3.6% float · 6.9d
Short vol59%
Last earningsMay 11, 2026
DataMar 2022–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Neutral
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+80% above
◦
Price vs 50-day avg
−4% below
◦
RSI (14)
44 · neutral
−
MACD trend
negative
◦
52-week position
58% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $5 › 200d $2 — 50d above 200d
+
Institutional flow
+41% holders QoQ · +25 funds added
−
Insider flow
Net -$1.2K over 90 days · 100% sells
−
Short interest
3.63% of float · ▲ +8.1% MoM · 6.9 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
52 holders — mid 3-yr range
Fundamentals
Excellent
+
EPS growth
+33% Y/Y
+
Balance sheet
net cash $19.9M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Sep 17, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+80% above
Bullish
Price vs 50-day avg
−4% below
Neutral
RSI (14)
44 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
58% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+41% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$1.2K over 90 days · 100% sells
Short interest
Rising
3.63% of float · ▲ +8.1% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
52 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $4 · 58%
52-wk high $7
vs 200-day avg +80%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANTX
this stock
AN2 Therapeutics, Inc.
|
$159.19M | +287.7% | — | — | 3.6% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANTX | -14.0% | +5.2% | +234.9% | -8.7% | +287.7% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -15.4% | +6.5% | +226.8% | -8.4% | +278.5% |